tbuckley/cabot-search huggingface dataset:
AB1074 In degenerative spine disease regular short courses of nsaids use are associated with greater kidney injury, compared with continuous nsaids intake and with absence of nsaids treatment
Authors: I.Z. Gaydukova, D. Bichurina, A. Rebrov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Nephrotoxicity in short-term or continuous NSAIDs administration is well-known problem of anti-inflammatory treatment. However, data about kidney injury in case of repeated short-term courses of NSAIDs treatment are limited. <h3>Objectives</h3> of the present study was to evaluate the kidney functions in patients with degenerative spine disease (DSD), taking NSAIDs in repeated short courses, compared with kidney function of patients with constant NSAIDs intake and to the healthy individuals. <h3>Methods</h3> The study included 137 patients, taking NSAIDs for DSD. 97 patients used NSAIDs in repeated short-term courses (3–5 courses per year, 7–14 days each course). 40 patients had continuous NSAIDs intake (5 and more days per week during the 1 year before the study). In the control group were involved healthy persons, did not treated with NSAIDs during the last year (n=40). Controls were sex- and age-matched with the DSD patients. Glomerular filtration rate (GFR) was calculated using CKD-EPI calculator. Albumin, α1-microglobulin and creatinine levels of urea were measured; albumin/creatinine and α1-microglobulin/creatinine ratios were calculated. <h3>Results</h3> Kidney function in DSD patients with NSAIDs intake and in healthy controls are presented in table 1. In patients with DSD and short NSAIDs' use a decrease in GFR of less than 90 ml/min/1.73 m<sup>2</sup> was evaluated in 61 (62.9%) of cases, GFR less than 60 ml/min/1.73 m<sup>2</sup> was detected in 11 (11.3%) patients. In patients with DSD and continuous NSAIDs use a decrease in GFR of less than 90 ml/min/1.73 m<sup>2</sup> was evaluated in 34 (85%) of cases, GFR less than 60 ml/min/1.73 m<sup>2</sup> was detected in 2 (12.5%) patients, p&lt;0.01, compared with controls and p≥0.05 compared with short-term use. GFR less than 60 ml/min/1.73 m<sup>2</sup> was found in 11 (11.3%) patients with DSD and short NSAIDs intake and in 0 (0%) of healthy volunteers (p=0.026). Albumin/creatinine ratio ≥30 mg/g was found in 74 (76.3%) patients with DSD with short-term NSAIDs use, in 22 (55%) patients with constant NSAIDs intake, and 9 (22.5%) healthy individuals (p&lt;0.01 for all intergroup differences). An increased level of microglobulin/creatinine ratio was found in 66% patients with DSD (in 82.4% cases of short-term and in 25% of continuous NSAIDs use, p&lt;0.01) and in 3 (7.5%) healthy individuals, p&lt;0.0001. <h3>Conclusions</h3> Decrease of the GFR less than 60 ml/min/1.73 m<sup>2</sup> and subclinical kidney injury in patients, treated with NSAIDs, was found frequently, than in healthy persons never treated with NSAIDs. The subclinical glomerular and tubular damage in patients with short-term courses of NSAIDs use exceeded glomerular and tubular changes in patients with constant NSAIDs use. <h3>Disclosure of Interest</h3> None declared
FRI0331 Trough concentration of mycophenolic acid correlates with renal function and serum albumin level in japanese patients with sle
Authors: R. Hiwa, K. Murakami, M. Mori, S. Nakagawa, S. Akizuki, N. Kuramoto, R. Nakashima, M. Hashimoto, H. Yoshifuji, M. Tanaka, K. Ohmura, T. Mimori
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mycophenolate mofetil (MMF) is an immunosuppressant used for treatment of lupus nephritis. MMF is converted to mycophenolic acid (MPA) by esterases, which is the active metabolite with pharmacological activities. A fixed dose of 2–3 g/day is administered as remission induction therapy.<sup>1</sup> The usefulness of therapeutic drug monitoring (TDM) of MMF has not been elucidated. Moreover, little is known about the factor that affects the concentration of MPA in Asian patients. <h3>Objectives</h3> The aim of this study is to investigate the factor that affects the trough concentration of MPA in Japanese patients with SLE. <h3>Methods</h3> We recruited the SLE cases whose trough concentrations of MPA were measured from 2014 to 2017 at Kyoto University Hospital. When trough concentrations were measured multiple times in each patient with the same dose of MMF, median concentration was used for the analyses. Linear regression analysis was performed to identify the factor that affects the trough concentration of MPA. The association of trough concentration of MPA and adverse effects of MMF was investigated as well. <h3>Results</h3> Total of 20 cases were recruited and 43 trough concentrations were included for the analyses. The median daily dose of MMF (g) was 1.5 (range; 0.25–3.0) and the median trough concentration of MPA (μg/ml) was 2.0 (range; 0.4–15.0). Linear regression analysis (table 1) revealed that trough concentration of MPA was correlated with daily dose of MMF (p=0.0081, r=0.40, figure 1A), serum albumin level (p=3.3x10–4, r=0.52, figure 1B) and creatinine clearance (p=1.8x10–5, r=−0.60, figure 1C). Daily dose of prednisolone and serum C4 level were correlated with trough concentration of MPA as well, though multicollinearity was found in these two variables and serum albumin or creatinine clearance. Multivariate analysis (table 2) revealed that serum albumin and creatinine clearance were independently associated with trough concentration of MPA (p=6.2x10–4 and 1.6 × 10–5, respectively). Adverse effects of MMF, such as diarrhoea and cytopenia, were not associated with trough concentration of MPA. <h3>Conclusions</h3> Trough concentration of MPA was correlated with daily dose of MMF, serum albumin level and creatinine clearance. <h3>Reference</h3> [1] Ann Rheum Dis2012;71:1771–82. <h3>Disclosure of Interest</h3> None declared
AB1056 Diagnosis value of percutaneous spinal needle biopsy in brucellar spondylodiscitis
Authors: O. Saidane, I. Oueslati, I. Mahmoud, A. Ben Tekaya, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> spondylodiscitis is a serious condition with a large variety of infectious etiology. Vertebral biopsy is needed to perform the microbiologic diagnosis when no causative organism is identified. CT-guided percutaneous spinal biopsy (CTSB) may reduce the risk of contamination and complications. <h3>Objectives</h3> The aim of this study is to determine the contribution of CTSB to the diagnosis of Brucellar spondylodiscitis. <h3>Methods</h3> we conducted a retrospective study on 27 patients admitted for Brucellar spondylodiscitis over a 17 years period [2000 to 2016]. The etiological diagnosis was based on Brucella agglutination test which was positive for all patients. Twelve patients had a CTSB with cytobacteriological and histological tests. <h3>Results</h3> twenty seven patients (17 men and 10 women) with a mean age of 54 years were included. Twenty six patients (96,3%) reported a spinal pain. This pain involved the lumbar spine (59.3%), the dorsal spine (18.5%) and less frequently the cervical spine (11,1%). Eight patients reported lombosciatica (29.6%). An etiological doubt subsisted in 12 cases and a CTSB was performed. Culture results were negative for 11 biopsy samples and one culture was positive to Staphylococcus in a case of a co-infection. The results of the histological examination showed chronic non-specific inflammation in 92.3% of cases. An infectious etiology was suspected histologically in 53.8% of cases and particularly of a pyogenic germ (23.1%). The biopsy was no contributive in one case <h3>Conclusions</h3> Our results suggest that CT-guided spinal biopsy is not useful to diagnose Brucellar spondylodiscitis. However, the absence of tuberculoid granuloma and caseous necrosis helped ruling out the tubercular origin <h3>Disclosure of Interest</h3> None declared
Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
Authors: Anne M. Fitzpatrick, Scott E. Gillespie, David T. Mauger, Brenda R. Phillips, Eugene R. Bleecker, Elliot Israel, Deborah A. Meyers, Wendy C. Moore, Ronald L. Sorkness, Sally E. Wenzel, Leonard B. Bacharier, Mario Castro, Loren C. Denlinger, Serpil C. Erzurum, John V. Fahy, Benjamin M. Gaston, Nizar N. Jarjour, Allyson Larkin, Bruce D. Levy, Ngoc P. Ly, Victor E. Ortega, Stephen P. Peters, Wanda Phipatanakul, Sima Ramratnam, W. Gerald Teague
Journal: Journal of Allergy and Clinical Immunology (2019)
Effective Chimeric Antigen Receptor T Cell Therapy for Relapsed and Refractory Acute Lymphoblastic Leukemia in Children Can be Administered Safely Under the Real-Time Monitoring of Th1/Th2 Cytokine Patterns Measured By the Cytometric Bead Array Technology
Authors: Yongmin Tang, Diying Shen, Lei Xiao, Hua Song, Fenying Zhao, Xiaojun Xu, Weiqun Xu, Di Wang, Juan Liang, Meixin Fang, Chan Liao, Sisi Li, Ning Zhao, Wei Huang
Journal: Blood (2018)
FRI0382 A study of mcp1 and lipocalin as urinary biomarkers in lupus nephritis
Authors: R. Ramamoorthy, T.N. Tamilselvam, B. Kumar
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Currently, major efforts have been undertaken to identify biomarkers that can predict impending lupus renal flare, development of chronic kidney disease or reflect renal histology at the time of the flare. <h3>Objectives</h3> This study aims to assess the correlation of urinary biomarkers MCP1 and NGAL with the disease activity in lupus nephritis. <h3>Methods</h3> This was a prospective study conducted in a tertiary care centre. 60 patients with SLE were recruited. They were divided into 3 groups, one with Active Lupus Nephritis (n=22), another with Inactive Lupus Nephritis (n=20) and a third formed of SLE patients with no renal involvement (n=18). For comparison another group of age and sex matched controls was taken (n=20). Disease activity was correlated with disease activity indices, baseline characteristics and biopsy. Urinary MCP1 and NGAL were measured. Statistical analysis using SPSS11.5 was done to find the correlation between levels of urinary biomarkers and disease activity. <h3>Results</h3> In patients with active LN, both UMCP1/Cr and UNGAL/Cr were significantly elevated (92.78, 76.11 pg/ml, p&lt;0.001). In both control group and SLE without renal involvement the values of UMCP1/Cr and UNGAL/Cr were normal (24.44, 22.22 pg/ml in control and 24.3, 22.80 pg/ml in SLE without renal involvement). In patients with inactive LN the values of UMCP1/Cr and UNGAL/Cr were observed to be significantly higher than control (44.18, 38.45 pg/ml, p&lt;0.005) and lower than those of active LN. Values of UMCP1/Cr and UNGAL/Cr were found to be in close correlation with mean rSLEDAI scores of active LN<sup>10</sup> and inactive LN(3.6). <h3>Conclusions</h3> Levels of urinary biomarkers UMCP1 and UNGAL were significantly elevated in active lupus nephritis and found to have excellent correlation with disease activity index and rSLEDAI scores. <h3>References</h3> [1] Susianti H, Iriane VM, Dharmanata S, Handono K, Widijanti A, Gunawan A, Kalim H. Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology2015Mar;22(1):65–71. doi:10.1016/j.pathophys.2014.12.003. [Epub 2015 Jan 6]. [2] Susianti H, et al. Urinary Neutrophil Gelatinase associated Lipocalin to monitor Lupus Nephritis Disease Activity. Biomark insights2015;10:80–87. <h3>Disclosure of Interest</h3> None declared
FRI0725-HPR Understanding the burden of rheumatoid arthritis using qualitative research: which impacts are not captured by patient-reported measures?
Authors: Y. Shaw, C. Zhang, R. Schumacher, D. McDonald, T.A. Simon, K. Michaud
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Existing measures of disease burden in rheumatoid arthritis (RA) include patient-reported measures (PRMs) of physical and mental functioning, symptoms and work disability. However, these measures may be inaccurate if interpreted by respondents in unintended ways and may not capture some impacts of RA of importance to patients. <h3>Objectives:</h3> To explore the perspectives of RA patients on PRMs used in The National Data Bank for Rheumatic Diseases (Forward) registry and to identify impacts of importance to patients that may not be captured by commonly used measures. <h3>Methods:</h3> Semi-structured ethnographic interviews were conducted with adult RA patients in the United States participating in Forward. Interviewees were asked to discuss the impact of RA on their lives and their perspectives on PRMs used in Forward. Interviews were audio-recorded and transcribed verbatim. Transcripts were analyzed for themes related to: 1) perspectives on PRMs, and 2) important impacts of RA. <h3>Results:</h3> We interviewed 18 patients aged 27–80 years, with RA durations of 4–40 years and Forward participation of 1–19 years. Participants9 perspectives on PRMs fell into 4 categories (table 1). Several patients doubted that the PRMs adequately captured the severity of their symptoms. Important impacts of RA not measured by Forward included: expenditures on adaptive devices and measures, impact on life goals and activities (educational and career plans, family responsibilities, and valued activities) and interaction with stressful life events (such as family deaths). <h3>Conclusions:</h3> Challenges in interpreting and answering questions may reduce the accuracy of PRMs of RA symptoms. The PRMs discussed by participants may not fully capture the impact of RA on patients9 financial burdens and on their pursuit of life goals and activities. Future efforts to improve the accuracy and comprehensiveness of burden of disease measurement in RA should help to address these issues. Use of qualitative methods (such as ethnography) may also help to illuminate aspects of living with RA that are not captured by existing PRMs. <h3>Disclosure of Interest:</h3> Y. Shaw Grant/research support from: Bristol-Myers Squibb, C. Zhang Grant/research support from: Bristol-Myers Squibb, Employee of: LIFT1428, R. Schumacher: None declared, D. McDonald Grant/research support from: Bristol-Myers Squibb, T. Simon Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, K. Michaud Grant/research support from: Bristol-Myers Squibb, Pfizer and Rheumatology Research Foundation, Employee of: University of Nebraska Medical Center and National Data Bank for Rheumatic Diseases
Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges
Authors: Zhenya Senyak, Ruben A. Mesa, Nicolaus Kroeger, Koen Van Besien, Wael Saber, Richard T. Silver, Attilio Orazi, Jeanne Palmer, Claire N. Harrison, Srdan Verstovsek, Uday Popat, Michelle J Woerhle, Ann Brazeau, Barbara Van Husen, Martin Prager, Chris Harper, Beatrice Larroque, Robyn Marie Scherber
Journal: Blood (2018)
AB1361 Seasonal sensitivities of disease activity İndices in rheumatoid arthritis
Authors: A. Şahin Eşkara, N. Taştekin, M. Birtane, N. Süt
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease which is primarily characterised by the inflammation of synovial joints. In rheumatoid arthritis, evaluation of the disease activity is very important in monitoring the disease progression and effectiveness of the treatment <h3>Objectives</h3> The aim of this study was to evaluate the seasonal sensitivity of disease activity indices (DAS28-ESR, DAS28-CRP, SDAI and CDAI) in rheumatoid arthritis. In addition, we investigated the presence of seasonal variation in disease activity in rheumatoid arthritis and its relation to vitamin D levels. <h3>Methods</h3> This is a prospective study. This study included female RA patients, who were diagnosed/verified according to 2010 ACR/EULAR criteria, with a diagnostic history of 5 years or older. The seasons were identified as spring (March, April, May), summer (June, July, August), autumn (September, October, November) and winter (December, January, February), and the study was completed with 85 patients. We assessed the disease activation with DAS28-ESR, DAS28-CRP, SDAI and CDAI scales, functional status with HAQ questionnaire, quality of life with the 36-Item Short Form Health Survey (SF-36), and presence of depression with beck depression inventory (BDI). Blood samples from patients were kept at appropriate storage conditions at −80 ° C, and serum levels of 25-OH vitamin D were analysed by the chemoimmunoassay method at the end of each season. <h3>Results</h3> The assessment of mean of DAS28-ESR and DAS28-CRP scores found that the disease activity showed statistically significant seasonal differences (p&lt;0.05). Although the assessment of mean of SDAI and CDAI scores showed that the disease activity was higher in the autumn season, this difference was not statistically significant (p&gt;0.05). There was no statistically significant correlation between the mean vitamin D levels and mean of DAS28-ESR, DAS28-CRP, SDAI, CDAI scores in any season (p&gt;0.05). <h3>Conclusions</h3> These results suggest that there may be seasonal variation in disease activity in RA and that DAS28-ESR and DAS28-CRP may be more sensitive than CDAI and SDAI in establishing this variation. There was no correlation between seasonal changes in disease activity and changes in serum 25-OH Vitamin D levels <h3>Reference</h3> [1] Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res2012;64(5):640–7. <h3>Disclosure of Interest</h3> None declared
Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation
Authors: Karen Sweiss, Gregory Sampang Calip, Jeremy Johnson, Hyunyoung Jeong, Damiano Rondelli, Pritesh Patel
Journal: Blood (2018)
SAT0452 Endothelium dysfunction in patients with systemic lupus erythematosus with and without nephritis
Authors: N. Mohannad, A.I. El Zawawy, M. Elbordeny, D. Emara, S. Ibrahim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Organ-specific manifestations in systemic lupus erythaematosus (SLE) are highly influenced by the inherent characteristic of the vasculature<sup>(1)</sup> Endothelial dysfunction might have significant roles in the pathogenesis of glomerular diseases.CD31 or platelet endothelial cell adhesion molecule-1 is known to have roles in angiogenesis, platelet function, thrombosis, and regulation of leukocyte migration through vascular walls<sup>(2)</sup> <h3>Objectives</h3> to assess the endothelium dysfunction in SLE patients (pts) and to determine its association with lupus nephritis (LN) <h3>Methods</h3> Study included 60 pts with SLE fulfilling the SLICC criteria for classification of SLE: 30 with(LN),30 SLE without LN and 10 matched healthy controls.Routine laboratory tests, lipid profile,renal functions, titres of autoantibodies [ANA,anti ds-DNA,anticardiolipin antibodies ACL(IgM, IgG),flowcytometry to detect PECAM-1/CD31,doppler ultrasound to detect FMD of the brachial artery and SLEDAI were done to all SLE pts.Pts with diseases known to affect endothelial function:smoking,DM,essential HTN,known CAD were excluded <h3>Results</h3> Correlation between FMD% and different parameters are shown in table 1.There was a statistical significant positive relation between CD31 and urea in LN(p=0.014),non LN(p=0.014), total SLE pts(p&lt;0.001),creatinine in non LN group(p=0.025), 24 hour protein in LN(p&lt;0.001), non LN(p&lt;0.001) and total SLE pts (p&lt;0.001),cholesterol in LN(p&lt;0.001), non LN(p=0.001) and total SLE pts(p&lt;0.001), LDL in LN(p=0.001), non LN(p=0.009) and total SLE pts(p&lt;0.001),TG in total pts(p=0.048),anti-dsDNA in LN(p=0.024) and total SLE pts(p=0.008),SLEDAI in LN(p=0.001) and total SLE pts(p&lt;0.001). <h3>Conclusions</h3> Endothelial dysfunction is the first step in the atherogenic process. FMD and CECs may be used as markers for endothelial dysfunction in SLE. FMD correlated with proteinuria and may be used as an early marker for LN.CECs may play a role in atherosclerosis, vasculitis and LN <h3>References</h3> [1] Sesin CA, et al. Shedding of endothelial protein C receptor contributes to vasculopathy &amp; renal injury in lupus: in vivo and in vitro evidence. Kidney Int2005. [2] Woodfi n A, et al. PECAM-1: a multi-functional molecule in inflammation &amp; vascular biology. Arterioscler Thromb Vasc Biol2007. <h3>Disclosure of Interest</h3> None declared
OP0296 The risk of deliberate self-harm in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study
Authors: B Kuriya, J. Widdifield, J. Luo, S. Vigod, N. Haroon
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Inflammatory arthritis is associated with the development of mental health disorders. However, there is limited data on the risk of serious mental health outcomes following a rheumatoid arthritis (RA) or ankylosing spondylitis (AS) diagnosis. <h3>Objectives</h3> To estimate the risk of deliberate self-harm in patients with ankylosing spondylitis or rheumatoid arthritis compared with the general population. <h3>Methods</h3> We evaluated population-based cohorts of RA (n=53,240) and AS (n=13,964), each matched 1:4 by age, sex, and calendar year (at diagnosis) with non-IA comparator cohorts in Ontario, Canada. Individuals with a history of mental illness or prior episode of deliberate self-harm were excluded. The outcome was a first emergency room presentation for deliberate self-harm, subsequent to RA or AS diagnosis, between April 1, 2002 and March 31, 2016. We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) for RA and AS, separately, versus the comparator groups, adjusting for demographic, clinical and health service utilisation variables. <h3>Results</h3> Individuals with AS were more likely to deliberately self-harm (incidence rate [IR] of 6.79/10,000 person years [PY] compared to 3.19/10,000 PY in comparators, with an adjusted HR 1.82 (95% CI: 1.26 to 2.62). Deliberate self-harm was also increased for individuals with RA (IR 3.51/10,000 PY) compared to comparators (IR 2.45/10,000 PY) only before (HR 1.43, 95% CI: 1.16 to 1.75), but not after covariate adjustment (HR 1.09, 95% CI: 0.88 to 1.36). The most frequent method of self-harm was poisoning (64% of attempts in AS, 81% in RA) or self-mutilation (36% in AS, 18% in RA). <h3>Conclusions</h3> There is a significantly increased rate of self-harm attempt in inflammatory arthritis and the risk is particularly elevated following a diagnosis of AS. These findings highlight the need for routine evaluation of self-harm behaviour as part of the management of chronic inflammatory arthritis. Understanding the mechanisms contributing to deliberate self-harm attempts will help tailor preventive strategies to reduce morbidity associated with this serious mental health outcome. <h3>Acknowledgements</h3> This work was funded by the Division of Rheumatology Pfizer Research Chair, University of Toronto <h3>Disclosure of Interest</h3> None declared
Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study
Authors: Paola Guglielmelli, Naseema Gangat, Giacomo Coltro, Terra L. Lasho, Giuseppe Gaetano Loscocco, Christy Finke, Benedetta Sordi, Mythri Mudireddy, Giada Rotunno, Natasha Szuber, Annalisa Pacilli, Rangit Reddy Vallapureddy, Maura Nicolosi, Domenico Penna, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Alessandro M. Vannucchi, Ayalew Tefferi
Journal: Blood (2018)